Travere Therapeutics Expects Record $410M in 2025 U.S. Sales on FILSPARI Surge and Eyes Key 2026 Milestones
FILSPARI Drives Exceptional Growth with 108% YoY Sales Jump
Travere Therapeutics closed 2025 on a high note, reporting preliminary U.S. net product sales of approximately $127 million for the fourth quarter and $410 million for the full year. The growth was fueled by FILSPARI’s expanding adoption in IgA nephropathy (IgAN), highlighted by all-time high patient demand and a 108% year-over-year revenue increase for the therapy. The company received 908 new patient start forms (PSFs) in Q4, indicative of robust ongoing demand and successful execution by commercial teams.
| Key FILSPARI Metrics (2025) | Q4 2025 | Full Year 2025 |
|---|---|---|
| New Patient Start Forms (PSFs) | 908 | - |
| Net Product Sales | $103M | $322M |
| YoY Growth (Net Product Sales) | 108% | - |
Focused on 2026: FSGS Approval In Sight and Pipeline Expansion Ahead
Looking ahead, Travere is targeting a potential landmark in January 2026 with the FDA’s decision on its supplemental New Drug Application (sNDA) for FILSPARI in focal segmental glomerulosclerosis (FSGS). If approved, FILSPARI would become the first and only approved therapy for this rare kidney disorder—potentially opening new commercial channels for the company. Travere reports it is well-positioned for the FSGS launch, pending regulatory clearance.
Parallel to this, the company plans to restart the pivotal Phase 3 HARMONY Study of pegtibatinase in classical homocystinuria (HCU) in Q1 2026, following manufacturing process optimizations. These clinical and regulatory milestones anchor Travere’s commitment to expand its rare disease portfolio and sustain financial growth.
International Expansion and Strategic Partnerships Fuel Further Momentum
Travere’s commercial progress is reinforced by global collaborations. In Q4 2025, the company received a $40 million milestone payment from CSL Vifor after achieving targeted market access. FILSPARI is now launched in multiple European markets, and the company remains eligible for additional commercial and regulatory milestone payments. A planned New Drug Application submission in Japan by partner Chugai Pharmaceutical could further globalize FILSPARI’s reach in 2026.
Financial Stability with Strong Year-End Cash Position
Travere ended 2025 with roughly $323 million in cash, cash equivalents, and marketable securities—a cash reserve that supports the company’s ongoing R&D and commercial activities as it eyes these pivotal 2026 milestones.
Updated Safety Guidance: Monitoring Remains Key for FILSPARI Therapy
Travere reaffirmed FILSPARI’s established risk profile, particularly noting the importance of its REMS program due to the risk of hepatotoxicity and embryo-fetal toxicity. Clinicians are urged to closely monitor liver enzymes, kidney function, and potassium levels, and to remain vigilant for potential drug interactions. FILSPARI is contraindicated during pregnancy and in combination with certain other therapies, underscoring the need for coordinated prescribing and monitoring.
| Key Safety Considerations | Guidance |
|---|---|
| Hepatotoxicity Risk | Regular liver enzyme monitoring, use restricted to REMS-enrolled patients/providers |
| Embryo-Fetal Toxicity | Contraindicated in pregnancy; effective contraception required during and post-treatment |
| Key Adverse Reactions (=5%) | Hyperkalemia, hypotension, peripheral edema, dizziness, anemia, acute kidney injury |
| Drug Interactions | Avoid coadministration with ARBs, ERAs, CYP3A inhibitors/inducers, P-gp/BCRP substrates, potassium-increasing agents |
Takeaway: Clinical Milestones and Financial Strength Set Stage for 2026
With a robust U.S. launch of FILSPARI, growing international partnerships, and advancing clinical programs, Travere Therapeutics is entering 2026 on strong operational and financial footing. Investors and those following the rare disease space may want to watch for the pivotal FDA decision on FILSPARI in FSGS early in the year, a restart of the HARMONY study in HCU, and further commercial developments from the global launch partners. As with all biopharma outlooks, continued regulatory review and real-world evidence will be key to sustaining momentum.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI